RG
ONXX

Redmile Group’s ONYX PHARMACEUTICALS INC ONXX Stock Holding History

Redmile Group’s Portfolio ONXX Stock Details ONXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-393,981
Closed -$34.2M – 72
2013
Q2 		$34.2M Buy
+393,981
New +$36.3M 6.03% 2

Other funds holding ONXX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
ACPU
Arrowgrass Capital Partners (US) Dover, Delaware $380M AUM 20.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Redmile Group's ONXX Position: Q3 2013 in Review

Redmile Group sold out of ONYX PHARMACEUTICALS INC (ONXX) in Q3 2013, closing a stake of 393,981 shares — an estimated $34.2M sold.

Redmile Group first reported a position in ONXX in Q2 2013 and held it in 1 quarter. The position peaked at $34.2M in Q2 2013. 258 funds tracked by Wall St. Rank hold ONXX as of Q3 2013.

  • Redmile Group reported no remaining ONYX PHARMACEUTICALS INC position as of Q3 2013 after selling out during the quarter.
  • Redmile Group sold 393,981 ONYX PHARMACEUTICALS INC shares in Q3 2013, an estimated $34.2M.
  • Redmile Group first reported a position in ONYX PHARMACEUTICALS INC in Q2 2013 and held it in 1 quarter.
  • Redmile Group's ONYX PHARMACEUTICALS INC position peaked at $34.2M in Q2 2013.
  • 258 funds tracked by Wall St. Rank held ONYX PHARMACEUTICALS INC as of Q3 2013.

Based on Redmile Group's 13F filing for Q3 2013, filed 14 Nov 2013.